Market Overview

UPDATE: Cantor Fitzgerald Upgrades Obagi Medical Products to Buy; Advisory Fees May Signal M&A Event

Related OMPI
Valeant Pharmaceuticals International Completes Tender Offer for Obagi Medical Products
Valeant Pharma Reports Receipt of Approval from Antimonopoly Committee of Ukraine for Obagi Offer

Cantor Fitzgerald upgraded Obagi Medical Products (NASDAQ: OMPI) from Hold to Buy and raised the price target from $15.00 to $19.00.

Cantor Fitzgerald analyst Irina Rivkind commented, "We think Obagi remains an attractive target in a space rife with consolidation. Management's "advisor" disclosure coupled with a potentially win-able proxy contest may heighten investor anticipation of an M&A event and we view management's nervousness about competition as conducive to a deal. We therefore incorporate a 50% probability of company takeout in the $21 range (4x 2013 sales) into our valuation which results in our upgrade and blended $19 PT."

Obagi Medical Products closed at $13.94 on Thursday.

Latest Ratings for OMPI

Apr 2013Cantor FitzgeraldMaintainsHold
Mar 2013Roth CapitalDowngradesBuyNeutral
Mar 2013Cantor FitzgeraldDowngradesBuyHold

View More Analyst Ratings for OMPI
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Upgrades Analyst Ratings


Related Articles (OMPI)

View Comments and Join the Discussion!

Partner Center